Status:

ACTIVE_NOT_RECRUITING

Trimethylamine N-oxide Effects of a Pomegranate Supplement Simultaneously With Carnitine (TESSA)

Lead Sponsor:

Quadram Institute Bioscience

Collaborating Sponsors:

Norfolk and Norwich University Hospitals NHS Foundation Trust

Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)

Conditions:

Healthy

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Trimethylamine N-oxide (TMAO) is produced in some individuals whose diets include meat, fish, and dairy.These foods are rich in L-carnitine. L-carnitine is metabolised by the liver and gut microorgani...

Detailed Description

The TESSA study is a 18 day randomised, double-blind, placebo-controlled two-arm crossover pilot study conducted at the NIHR (National Institute for Health and Care Research) Norfolk Clinical Research...

Eligibility Criteria

Inclusion

  • Inclusion criteria (First phase):
  • Individuals who regularly eat meat (4 portions of meat per week for at least 2 months prior to enrolment in the study).
  • Aged 18 and older.
  • Body Mass Index (BMI) between 18.5 - 30 kg/m2.
  • Living within 40 miles from the Norwich Research Park.
  • Inclusion criteria (Second phase)
  • meets first phase inclusion criteria
  • TMAO producer (plasma TMAO increase of \>5 µM and \>50% after L-carnitine ingestion.
  • Exclusion criteria:
  • Consume an entirely vegan, vegetarian, or pescatarian diet within the last two months.
  • Do not have access to a freezer to store some provided meals and ice packs.
  • Have a known allergy to the tablets, capsules (i.e., pomegranate), or standardised meals such as wheat, eggs, milk, nuts, and soybeans.
  • Have difficulty swallowing, a swallowing disorder, or are unable to swallow four capsules (the size of a peanut) and three L carnitine tablets consecutively within a time span of ten minutes.
  • Have bowel movements less than five times a week.
  • Are a current smoker (or stopped smoking for less than 3 months).
  • Consume more than 14 units of alcohol per week (for example, a pint of beer or a 175 mL glass of wine each count as two units).
  • Are pregnant or breastfeeding.
  • Have anaemia or any conditions or medications that may hinder clotting. This will be assessed on a case-by-case basis.
  • Have high or low blood pressure (i.e., ≤90/60 or ≥160/100 mmHg).
  • Have a medical condition or take medications that may affect the primary outcome of this study, such as but not limited to diabetes, liver disease, hypo/hyperthyroidism, or fish odour syndrome. This will be assessed on a case-by-case basis.
  • Have had gastrointestinal disease or surgical procedures that may affect the primary outcome of this study. This will be assessed on a case-by-case basis.
  • Have known or a history of kidney disease, this will be determined by the medical advisor using blood urea nitrogen and creatinine levels in the participant's blood.
  • Regularly use bowel cleansing techniques like colonic irrigation or laxatives.
  • Had an infection or received antibiotics within a month prior to this study.
  • Regularly take dietary supplements that may affect the primary outcome measure of this study, such as fish oil or L carnitine supplements.
  • Are currently undergoing active treatment for cancer or heart disease.
  • Participated in another dietary intervention study within the last four months.
  • Have donated a large quantity of blood within the last 16 weeks. Registered donors should abstain from blood donations for the duration of the study.
  • Are a person related to or living with a member of the study team.
  • Are unable to give written or verbal informed consent.
  • Participant is unable to provide GP (General Practitioner) contact details.
  • Have symptoms of Coronavirus infection (COVID-19), been asked to self-isolate, or have been diagnosed with COVID-19 in the last 14 days.

Exclusion

    Key Trial Info

    Start Date :

    August 12 2024

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 31 2027

    Estimated Enrollment :

    39 Patients enrolled

    Trial Details

    Trial ID

    NCT06518343

    Start Date

    August 12 2024

    End Date

    May 31 2027

    Last Update

    June 15 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Quadram Institute

    Norwich, Norfolk, United Kingdom, NR4 7UQ